(CercleFinance.com) – GenSight Biologics announces today that the efficacy and safety data of patients with Leber Hereditary Optic Neuropathy and carriers of the ND4 mutation treated with lenadogene nolparvovec (LUMEVOQÒ, GS010) within the framework of Early Access, were presented at the Annual Meeting of the North American Neuro-Ophthalmology Society.
The data was collected in the United States, France, Italy and the United Kingdom.
‘Efficacy and safety data from these early access programs confirm LUMEVOQ as a real option for LHON patients with the ND4 mutation,’ said Dr. Catherine Vignal-Clermont, Head of Service at the Rothschild Foundation in Paris and the Center Hospitalier National d’Ophtalmologie des Quinze-Vingts in Paris.
The data confirmed the efficacy and safety profile of LUMEVOQ in real-life situations. The mean change in visual acuity variation one year after treatment in all eyes was an improvement of 22.5 ETDRS letters. Improvement was better in patients who received bilateral injections.